The future of the global viral vector manufacturing market looks promising with opportunities in the pharmaceutical & biopharmaceutical and research institutes markets. The global viral vector manufacturing market is expected to reach an estimated $3 billion by 2030 with a CAGR of 18.7% from 2024 to 2030. The major drivers for this market are increasing demand for viral vector-based therapies, growing investment in viral vector manufacturing, and technological advancements in viral vector manufacturing.
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the viral vector
manufacturing market by type (adenovirus, retrovirus, adeno-associated virus,
lentivirus, plasmid DNA, and others), workflow (upstream manufacturing and
downstream manufacturing), application (cell & gene therapy, vaccinology,
and research & other applications), end use (pharmaceutical & biopharmaceutical,
research institutes, and others), and region (North America, Europe, Asia
Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, cell
& gene therapy, vaccinology, and research & other applications are the
major segments of viral vector manufacturing market by application. Lucintel
forecasts that cell and gene therapy is expected to witness highest growth over
the forecast period due to growing demand for cell and gene therapies for the
treatment of a wide range of diseases, including cancer, rare diseases, and
genetic disorders.
Within this market,
pharmaceutical and biopharmaceutical will remain the largest segment due to the
fact that these pharmaceutical and biopharmaceutical companies companies are
developing and commercializing viral vector-based therapies for a wide range of
diseases, including cancer, rare diseases, and infectious diseases.
North America is
expected to witness highest growth over the forecast period due to increasing
demand for viral vector-based therapies from the pharmaceutical and
biotechnology industries in the region.
Merck, Lonza, Fujifilm Diosynth
Biotechnologies, Thermo Fisher Scientific, Cobra Biologics, Catalent, Wuxi
Biologics, Takara Bio, Waisman Biomanufacturing, and Genezen Laboratories are
the major suppliers in the viral vector manufacturing market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment